Myeloproliferative neoplasms: The era of JAK2 mutations and more…

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: Myeloproliferative neoplasms: The era of JAK2 mutations and more… ; volume:29 ; number:04 ; year:2008 ; pages:4-5
Indian journal of medical & paediatric oncology ; 29, Heft 04 (2008), 4-5

Contributor: Saxena, Renu
Gupta, Sanjeev Kumar

DOI: 10.4103/0971-5851.51396

URN: urn:nbn:de:101:1-2022031216483175791016

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:29 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Saxena, Renu
Gupta, Sanjeev Kumar

Other Objects (12)

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors

SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms

MPL W515 L/K mutations in myeloproliferative neoplasms

CALR mutations in myeloproliferative neoplasms : An unfolding story

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Hochschulschrift

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Targeted therapies for myeloproliferative neoplasms

Esophageal lesions in myeloproliferative neoplasms

Novel therapeutics in myeloproliferative neoplasms

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors

SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms

MPL W515 L/K mutations in myeloproliferative neoplasms

CALR mutations in myeloproliferative neoplasms : An unfolding story

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Hochschulschrift

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Targeted therapies for myeloproliferative neoplasms

Esophageal lesions in myeloproliferative neoplasms

Novel therapeutics in myeloproliferative neoplasms

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors

SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms

MPL W515 L/K mutations in myeloproliferative neoplasms

CALR mutations in myeloproliferative neoplasms : An unfolding story

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Hochschulschrift

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Targeted therapies for myeloproliferative neoplasms

Esophageal lesions in myeloproliferative neoplasms

Novel therapeutics in myeloproliferative neoplasms

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Myeloproliferative neoplasms: The era of JAK2 mutations and more…

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors

SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms

MPL W515 L/K mutations in myeloproliferative neoplasms

CALR mutations in myeloproliferative neoplasms : An unfolding story

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Targeted therapies for myeloproliferative neoplasms

Esophageal lesions in myeloproliferative neoplasms

Novel therapeutics in myeloproliferative neoplasms

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors

SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms

MPL W515 L/K mutations in myeloproliferative neoplasms

CALR mutations in myeloproliferative neoplasms : An unfolding story

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Targeted therapies for myeloproliferative neoplasms

Esophageal lesions in myeloproliferative neoplasms

Novel therapeutics in myeloproliferative neoplasms

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors

SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms

MPL W515 L/K mutations in myeloproliferative neoplasms

CALR mutations in myeloproliferative neoplasms : An unfolding story

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms

Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms

Targeted therapies for myeloproliferative neoplasms

Esophageal lesions in myeloproliferative neoplasms

Novel therapeutics in myeloproliferative neoplasms

Related objects

Reset password